Metabolic abnormalities: triglyceride and low-density lipoprotein

被引:73
作者
Krauss, RM
Siri, PW
机构
[1] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA
[2] Lawrence Berkeley Natl Lab, Dept Genome Sci, Berkeley, CA 94720 USA
[3] Univ Calif Berkeley, Dept Nutrit Sci, Berkeley, CA 94720 USA
关键词
D O I
10.1016/j.ecl.2004.03.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased plasma triglyceride and reduced high-density lipoprotein cholesterol are key features of the metabolic syndrome. Although elevated low-density lipoprotein cholesterol is not an integral characteristic of this syndrome, there is commonly an increase in the proportion of small, dense low-density lipoprotein particles. Together, these abnormalities constitute the atherogenic dyslipidemia of the metabolic syndrome. This article reviews the pathophysiology of altered triglyceride and low-density lipoprotein metabolism in the metabolic syndrome, outlines the relationship of these lipoprotein abnormalities to increased risk of coronary heart disease, and highlights the application of this information to clinical practice. The role of reduced high-density lipoprotein in the metabolic syndrome is discussed elsewhere in this issue.
引用
收藏
页码:405 / +
页数:12
相关论文
共 56 条
[31]  
Lamarche B, 2001, CAN J CARDIOL, V17, P859
[32]   Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status - Relation to plasma triglyceride and apolipoprotein B concentrations [J].
Laws, A ;
Hoen, HM ;
Selby, JV ;
Saad, MF ;
Haffner, SM ;
Howard, BV .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) :64-71
[33]  
Lindgren F.T., 1972, BLOOD LIPIDS LIPOPRO, P181
[34]   Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS) - Treatment effects and relation to coronary angiographic progression [J].
Mack, WJ ;
Krauss, RM ;
Hodis, HN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (05) :697-704
[35]   Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the stanford coronary risk intervention project [J].
Miller, BD ;
Alderman, EL ;
Haskell, WL ;
Fair, JM ;
Krauss, RM .
CIRCULATION, 1996, 94 (09) :2146-2153
[36]   LIPOPROTEIN SUBSTRATES OF LIPOPROTEIN-LIPASE AND HEPATIC TRIACYLGLYCEROL LIPASE FROM HUMAN POST-HEPARIN PLASMA [J].
MUSLINER, TA ;
HERBERT, PN ;
KINGSTON, MJ .
BIOCHIMICA ET BIOPHYSICA ACTA, 1979, 575 (02) :277-288
[37]   LDL size and risk of coronary heart disease in elderly men and women [J].
Mykkänen, L ;
Kuusisto, J ;
Haffner, SM ;
Laakso, M ;
Austin, MA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (11) :2742-2748
[38]   The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat [J].
Nieves, DJ ;
Cnop, M ;
Retzlaff, B ;
Walden, CE ;
Brunzell, JD ;
Knopp, RH ;
Kahn, SE .
DIABETES, 2003, 52 (01) :172-179
[39]   Lipoprotein heterogeneity and apolipoprotein B metabolism [J].
Packard, CJ ;
Shepherd, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (12) :3542-3556
[40]   RELATION OF TRIGLYCERIDE-METABOLISM AND CORONARY-ARTERY DISEASE - STUDIES IN THE POSTPRANDIAL STATE [J].
PATSCH, JR ;
MIESENBOCK, G ;
HOPFERWIESER, T ;
MUHLBERGER, V ;
KNAPP, E ;
DUNN, JK ;
GOTTO, AM ;
PATSCH, W .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (11) :1336-1345